PetrelintideResearch, Evidence & Safety Profile

Petrelintide is an investigational peptide drug developed by Zealand Pharma (Copenhagen, Denmark) and co-developed with F. Hoffmann-La Roche AG since March 2025. It is a long-acting analog of amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Petrelintide is designed for once-weekly subcutaneous administration as a potential foundational therapy for people living with overweight and obesity. It belongs to a different mechanistic class than the GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) and may complement rather than replace them.

The Phase 2 ZUPREME-1 trial, with topline results announced March 2026, reported a mean body weight reduction of approximately 10.7% at 42 weeks in the highest-dose petrelintide arm versus 1.7% in the placebo group. Among participants who completed dose escalation in that cohort, 98% reached the planned maintenance dose — a tolerability signal that distinguishes the drug from incretin-class therapies, where dose-limiting nausea and gastrointestinal effects are common. On April 29, 2026, Roche and Zealand announced that petrelintide will advance into Phase 3 chronic-weight-management trials beginning in the second half of 2026.

Roche and Zealand have also disclosed plans for a Phase 2 trial evaluating the combination of petrelintide with CT-388, Roche's investigational dual GLP-1/GIP receptor agonist. The combination strategy reflects a working hypothesis in the field that amylin agonism and incretin agonism may produce additive or synergistic effects on body weight by acting through complementary satiety pathways.

As of May 2026, petrelintide is not approved by the U.S. Food and Drug Administration or any other regulatory agency for any indication. It is in Phase 2 clinical development with Phase 3 anticipated H2 2026.

Regulatory caution: Petrelintide is an investigational compound. It has not been reviewed for safety and efficacy at any dose for any indication outside of clinical trial protocols. Any source claiming to supply petrelintide outside of an approved clinical trial should be regarded with serious skepticism — identity, purity, and safety of such products cannot be verified.

Petrelintide is a long-acting analog of human amylin, the second hormone secreted by pancreatic beta cells alongside insulin. Native amylin has a half-life measured in minutes, so a clinically usable amylin therapy requires structural modifications that resist enzymatic degradation and extend pharmacokinetics enough to support once-weekly dosing. Petrelintide is designed to do this while retaining selective amylin receptor activity.

• Amylin receptor activation: Amylin receptors are heterodimeric complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Activation of these receptors slows gastric emptying, reduces post-meal glucagon secretion, and signals through hindbrain centers to promote a feeling of satiety and reduce caloric intake.
• Restoration of leptin sensitivity: A growing body of preclinical and clinical evidence indicates that amylin agonism increases central nervous system sensitivity to leptin — the adipocyte-derived hormone that normally signals long-term energy stores to the hypothalamus. In obesity, leptin signaling is typically blunted (so-called "leptin resistance"). Amylin analogs may partially restore that signaling, addressing a mechanism that GLP-1 and GIP agonists do not directly target.
• Complementarity with incretin therapies: Because amylin and the incretins (GLP-1, GIP) act through distinct receptor systems and largely distinct neural circuits, combination strategies are an active area of clinical investigation. The planned petrelintide + CT-388 Phase 2 trial is one of several efforts in the field to test whether amylin + incretin combinations produce greater weight loss than either class alone.

The net result of amylin receptor activation is delayed gastric emptying, dampened post-prandial glucagon, restored leptin signaling, and reduced caloric intake — a profile that overlaps with but is mechanistically distinct from incretin agonism.

The following potential benefits are based on Phase 2 human clinical trial data (ZUPREME-1 topline release, March 2026) and earlier Phase 1 dose-finding work. All findings are from controlled clinical trials and may not be representative of uncontrolled use. Phase 3 data does not yet exist.

• Body weight reduction: Phase 2 ZUPREME-1 reported approximately 10.7% mean body weight reduction versus 1.7% placebo at 42 weeks in the highest-dose arm. The magnitude is below the published Phase 2 results for retatrutide (24.2% at 48 weeks) and tirzepatide (≈20% at 72 weeks in Phase 3) — but the comparison is imperfect because trial designs, populations, and durations differ.
• Tolerability: 98% of participants in the highest-dose cohort reached the planned maintenance dose. By contrast, GLP-1 and triple-agonist trials commonly report dose-limiting nausea, vomiting, and discontinuation rates ranging from 4% to 16% depending on dose. The improved tolerability is one of the principal reasons petrelintide is being positioned as a "foundational" therapy that may be combined with other agents.
• Restoration of leptin sensitivity (mechanistic): Preclinical and clinical evidence suggests amylin agonism re-sensitizes the central nervous system to leptin signaling. The clinical relevance of this mechanism for long-term weight maintenance is plausible but not yet established in published outcome data.
• Combination potential: Petrelintide is being studied in combination with CT-388 (a GLP-1/GIP dual agonist) in a planned Phase 2 trial. The hypothesis is that amylin + incretin agonism produces additive weight-loss effects with a more favorable side-effect profile than higher-dose incretin monotherapy.

It is important to interpret Phase 2 figures with appropriate caution. Weight-loss magnitude in incretin and amylin trials commonly evolves between Phase 2 and Phase 3 — sometimes upward (longer trial duration captures more sustained loss) and sometimes downward (broader populations dilute the strongest responder effect). Phase 3 ZUPREME readouts are the next meaningful data point.

Petrelintide's safety profile, as reported from Phase 2 ZUPREME-1, is favorable relative to the GLP-1 receptor agonist class. Phase 3 data does not yet exist.

• Gastrointestinal effects: Nausea, vomiting, and other gastrointestinal adverse events were reported in Phase 2 but at lower rates and milder severity than commonly reported with GLP-1 agonists at comparable weight-loss magnitudes. The 98% maintenance-dose-completion rate is one quantitative reflection of this.
• Injection site reactions: As with other once-weekly subcutaneous peptide therapies, mild injection site reactions (redness, irritation) have been reported. These are generally transient and self-limiting.
• Hypoglycemia: Amylin agonism, like GLP-1 agonism, is largely glucose-dependent in its insulin-secretagogue effect. Risk of hypoglycemia from petrelintide alone is low; risk increases substantially when combined with insulin or sulfonylureas.
• Long-term safety: As an investigational compound currently in Phase 2 with Phase 3 not yet started, petrelintide's long-term safety profile is not characterized. Phase 3 trials and post-market surveillance (if approved) will establish the long-term risk picture.
• Combination safety: Safety of petrelintide combined with incretin agonists (CT-388, semaglutide, tirzepatide) is being evaluated in upcoming trials. Combining therapies in this class outside of a clinical trial protocol is not supported by evidence and is not advisable.

The native amylin analog pramlintide (Symlin), approved for diabetes management, carries an FDA boxed warning for severe hypoglycemia when combined with insulin. Whether and how this class-level concern translates to petrelintide and its weight-management indication will be characterized further as Phase 3 data emerges.

Disclaimer: Petrelintide is investigational and not approved for any indication. The following information reflects publicly disclosed clinical trial design for educational purposes only. These are not recommendations for self-administration.

Petrelintide is being developed for once-weekly subcutaneous administration. Phase 2 ZUPREME-1 used a multi-step dose escalation protocol designed to optimize tolerability before reaching maintenance dosing at 42 weeks. Specific maintenance-dose magnitudes have been disclosed at the company-investor level but full Phase 2 publication is pending.

Phase 3 trials are scheduled to begin in the second half of 2026. Phase 3 dose selection will follow standard regulatory practice — anchored on the Phase 2 dose-response data and intended to characterize efficacy and safety across a clinically relevant range.

As of May 2026, petrelintide has the most advanced clinical data set of any selective amylin analog in development for chronic weight management. The published evidence base remains primarily at the company-disclosure and conference-presentation level pending peer-reviewed Phase 2 publication.

• Phase 2 ZUPREME-1 (topline March 2026): Phase 2 trial in adults with overweight or obesity. Topline results reported approximately 10.7% mean body weight reduction at 42 weeks in the highest-dose petrelintide arm versus 1.7% in the placebo arm. 98% of participants in the highest-dose cohort completed dose escalation to the planned maintenance dose. Full peer-reviewed publication is anticipated; presentation at obesity-focused medical conferences is expected.
• Phase 3 program (H2 2026 launch announced April 29, 2026): Roche and Zealand jointly announced advancement to Phase 3. Trials are planned to evaluate petrelintide for chronic weight management in adults with overweight and obesity. Specific endpoint design and trial sizes will be disclosed at trial registration.
• Petrelintide + CT-388 combination Phase 2 (planned 2026): A Phase 2 trial of petrelintide combined with CT-388 — Roche's investigational GLP-1/GIP dual agonist — is planned to launch later in 2026. The trial will test the working hypothesis that amylin + incretin combinations produce greater weight loss than either monotherapy with a favorable tolerability profile.
• Partnership economics: In March 2025, Roche entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide. The deal included approximately $1.65 billion in upfront and near-term milestones, with total deal value reported in the multi-billion-dollar range. This investment level reflects the perceived strategic value of an amylin-class foundational therapy.

The amylin class has long-standing pharmacological proof-of-concept through pramlintide (Symlin), an approved diabetes adjunct since 2005. Petrelintide is one of several next-generation amylin agonists in development; cagrilintide, partnered with semaglutide as CagriSema, is the most clinically advanced amylin + incretin combination from a competing pipeline. Comparative data between petrelintide-class and cagrilintide-class therapies does not yet exist.

As of May 2026, petrelintide is an investigational new drug (IND) in active Phase 2 clinical development with Phase 3 trials announced for H2 2026. It has not received FDA approval, EMA approval, or approval from any other regulatory agency for any indication.

• United States: Investigational. Available only within approved clinical trial protocols. Not compoundable — petrelintide is a proprietary peptide produced through company-controlled manufacturing processes, not a generic peptide that compounding pharmacies can legally replicate.
• European Union: No regulatory status established. Phase 3 trials are being designed for global development.
• Off-label or grey market access: Unlike some research-grade peptides that are sold in unregulated channels, petrelintide's status as a proprietary investigational drug should make unauthorized access extremely limited. Any source claiming to supply petrelintide outside of a clinical trial should be regarded with serious skepticism — identity, purity, and safety of such products cannot be verified, and the legal exposure to suppliers and purchasers is significant.
• Expected timeline: Phase 3 trials launching H2 2026. NDA filing timing depends on Phase 3 trial design and primary-endpoint duration; market availability would not be expected before 2028 at the earliest. This is speculative and depends on the outcome of Phase 3 readouts and regulatory review.